CapsoVision, Inc.
CapsoVision, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.6 million, up 15.3% from fiscal 2024. In the quarter to June 2026, revenue grew 9.89%, EPS grew 92.6% and free cash flow fell 84.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CV
CapsoVision, Inc. (CV) Altman Z-score
CapsoVision, Inc.'s Altman Z-score for fiscal 2025 is 17.04, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 17.04 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.67 | — | 0.81 | |
| Retained earnings / total assets | (8.57) | — | −12.00 | |
| EBIT / total assets | (1.40) | — | −4.64 | |
| Market value of equity / total liabilities | 53.53 | — | 32.12 | |
| Sales / total assets | 0.75 | — | 0.75 | |
| Altman Z-score | Safe zone | 17.04 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −30.12 | ||
Z and Z″ put CapsoVision, Inc. in different zones: safe zone by Z, distress zone by Z″.
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| CV CapsoVision, Inc. | 17.0× |
| VMD Viemed Healthcare, Inc. compare | 5.6× |
| INFU InfuSystems Holdings, Inc. compare | 3.7× |
| SI Shoulder Innovations, Inc. compare | 2.5× |
| OFIX ORTHOFIX MEDICAL INC. compare | 1.3× |
| CLPT ClearPoint Neuro, Inc. compare | 0.4× |
| QSI Quantum-Si Incorporated compare | 0.4× |
| SENS Senseonics Holdings, Inc. compare | −9.8× |
| RCEL Avita Medical Inc. compare | −12.0× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets